New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-AHK vs Semaglutide

Pal-AHK vs Semaglutide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-AHK
GLP-1 / Weight Loss Agonists
Semaglutide
Summary
Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
Extended (lipid depot effect in stratum corneum)
~7 days
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
0.01–0.05% in formulation
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Frequency
Once or twice daily
Once weekly, subcutaneous
Key Benefits
  • Enhanced skin penetration vs. unmodified AHK-Cu
  • Stimulates dermal collagen and elastin production
  • Promotes hair follicle anagen phase
  • Antioxidant and wound healing activity
  • Firming and plumping effect on aging skin
  • Improved bioavailability via lipid bilayer incorporation
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
Side Effects
  • Generally well-tolerated
  • Mild irritation at high concentrations in sensitive skin
  • Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
Stacks With